Skip to main content
EarningsCallAI

Updated May 2026 · SEC EDGAR data

How Did Eli Lilly and Company (LLY) Perform?

Eli Lilly and Company (LLY) is currently classified TAILWIND on the EarningsCallAI operator signal, with HIGH confidence, drawn from 8 quarters of SEC EDGAR XBRL filings and earnings call commentary. Latest reported revenue is $19.8B. Revenue grew +73.1% year-over-year. EPS came in at $8.26, with net income of $7.4B. Sector: Healthcare.

Headline Numbers

$19.8B
Revenue
+73.1%
Rev Growth (YoY)
$8.26
EPS
$7.4B
Net Income

What the TAILWIND Signal Means

Eli Lilly and Company is currently classified TAILWIND with high confidence. The structured trend across recent quarters shows revenue acceleration; management commentary in the call backs that up with positive demand and pricing language. For operators in adjacent markets, that is a constructive backdrop.

Revenue Trajectory

Eli Lilly and Company grew revenue +73.1% year-over-year, an exceptional pace. Acceleration of this magnitude is unusual at the S&P 500 scale and typically reflects either a hot product cycle, a major acquisition, or a recovery from a depressed prior-year comparison. Worth checking which is which before extrapolating.

Net income of $7.4B on $19.8B of revenue works out to a 37.4 percent net margin, exceptionally strong profitability. Margins this high typically reflect software-style scale economics, a dominant market position, or a particularly favorable product mix.

Quarterly Profile

MetricValue
Operator SignalTAILWIND
Signal ConfidenceHIGH
SectorHealthcare
Quarters Tracked8

How the Signal Is Calculated

The EarningsCallAI operator signal blends a quantitative read of revenue trajectory across the most recent four to eight quarters with a qualitative read of management commentary in the earnings call. Both inputs come from primary public sources: SEC EDGAR XBRL filings for structured financials, and SEC Form 8-K earnings releases for management commentary. Where the two inputs agree, signal confidence is HIGH; where they conflict, confidence drops. Read the full methodology for the formal classification rules.

Frequently Asked Questions

How did Eli Lilly and Company perform in its latest earnings report?

Eli Lilly and Company reported $19.8B in revenue and $8.26 EPS in the most recent quarter filed on SEC EDGAR. Year-over-year revenue growth was +73.1%. The current operator signal is TAILWIND with HIGH confidence.

What does Eli Lilly and Company's TAILWIND signal mean?

TAILWIND means revenue is accelerating across recent quarters and management commentary is positive on demand. For operators in adjacent markets, the read is constructive: budgets in this space are likely healthy.

Where does Eli Lilly and Company's data come from?

All structured financials, revenue, EPS, net income, growth rates, are pulled directly from Eli Lilly and Company's SEC EDGAR XBRL filings (10-K, 10-Q). Operator signal classification is EarningsCallAI methodology, applied consistently across all S&P 500 companies and updated each earnings season. EDGAR data is in the public domain.

What sector is Eli Lilly and Company in?

Eli Lilly and Company is classified in the Healthcare sector. The classification follows standard S&P 500 sector taxonomy. To see how Eli Lilly and Company compares to other companies in the same sector, browse the sector page or use the side-by-side comparison tool.

Is the TAILWIND signal investment advice?

No. The operator signal is built for business operators evaluating market demand and competitive trends, not for stock trading decisions. A TAILWIND signal does not mean buy the stock; a HEADWIND signal does not mean sell. Always consult a licensed financial advisor before making investment decisions.

Eli Lilly and Company (LLY) is currently classified TAILWIND on the EarningsCallAI operator signal, with HIGH confidence, drawn from 8 quarters of SEC EDGAR XBRL filings and earnings call commentary. Latest reported revenue is $19.8B. Revenue grew +73.1% year-over-year. EPS came in at $8.26, with net income of $7.4B. Sector: Healthcare.